DYNT (Dynatronics) Beginning Cash Position: $0.38 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Dynatronics Beginning Cash Position?

Dynatronics DYNT Beginning Cash Position is $0.38 Mil as of Sep. 2025. The stock has 8 warning signs investors should review.

Dynatronics's Beginning Cash Position for the quarter that ended in Sep. 2025 was $0.38 Mil.

Dynatronics's quarterly Beginning Cash Position declined from Mar. 2025 ($0.84 Mil) to Jun. 2025 ($0.23 Mil) but then increased from Jun. 2025 ($0.23 Mil) to Sep. 2025 ($0.38 Mil).

Dynatronics's annual Beginning Cash Position declined from Jun. 2023 ($0.70 Mil) to Jun. 2024 ($0.55 Mil) and declined from Jun. 2024 ($0.55 Mil) to Jun. 2025 ($0.53 Mil).

Dynatronics Beginning Cash Position Related Terms

Dynatronics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Dynatronics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynatronics Beginning Cash Position Chart

Dynatronics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.32 6.25 0.70 0.55 0.53

Dynatronics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.33 0.84 0.23 0.38

Dynatronics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.38 Mil mean?
Dynatronics (DYNT) has a Beginning Cash Position of $0.38 Mil as of Sep. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Dynatronics and its competitors.
Is Dynatronics' Beginning Cash Position too high?
Dynatronics' current Beginning Cash Position is $0.38 Mil.
How does Dynatronics' Beginning Cash Position compare to VERO and SSKN?
Dynatronics' Beginning Cash Position of $0.38 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Dynatronics and its competitors. Dynatronics's current Beginning Cash Position is $0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynatronics stock overvalued right now?
Dynatronics (DYNT) has a current Beginning Cash Position of $0.38 Mil. The stock's GF Value™ is $0.13, compared to a current price of $0.04 — trading 68.7% below its estimated fair value. The current Beginning Cash Position is $0.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Dynatronics (DYNT), the current Beginning Cash Position is $0.38 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dynatronics Business Description

Address 1200 Trapp Road, Eagan, MN, USA, 55121
Dynatronics Corp is a medical device company specializing in high-quality restorative products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The company designs, manufactures, and markets a broad portfolio of products, including orthopedic soft bracing, treatment tables, therapeutic modalities such as electrotherapy and ultrasound, and rehabilitation equipment. Serving orthopedists, physical therapists, chiropractors, athletic trainers, and hospitals, the company is known for its trusted brands like Bird & Cronin, Solaris, Hausmann, and PROTEAM. The company focuses on innovation and quality to support healthcare professionals in improving patient outcomes across diverse clinical settings.